Industries > Pharma > Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027

Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027

Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, Other

PUBLISHED: 29 June 2017
PAGES: 172
PRODUCT CODE: PHA0207
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0207 Categories: ,

The Non-Small Cell Lung Cancer (NSCLC) Drugs market is estimated at $7.86bn in 2016 and is expected to grow at a CAGR of 4.9% in the first half of the forecast period. The market is expected to grow at a CAGR of 3.2% during the full forecast period. In 2016, the chemotherapy segment generated a revenue of $3.28bn and represented 41.7% of the total NSCLC drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 172-page report you will receive 133 charts – all unavailable elsewhere.

The 172-page report provides clear detailed insight into the Non-Small Cell Lung Cancer (NSCLC) Drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Non-Small Cell Lung Cancer (NSCLC) Drugs market forecasts from 2017-2027

• This report also breaks down the revenue forecast for the main therapeutic segments:
• Chemotherapy
• EGFR and ALK Inhibitors
• VEGF / VEGFR Inhibitors
• Immunotherapy

Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027

• This report provides revenue forecast to 2027 for the leading drugs in this market:
Alimta (pemetrexed) by Eli Lilly
Avastin (bevacizumab) by Roche
Tarceva (erlotinib) by Roche
Iressa (gefitinib) by AstraZeneca
Gilotrif (afatinib) by Boehringer Ingelheim
Xalkori (crizotinib) by Pfizer
Abraxane (paclitaxel Protein-Bound) by Celgene
Taxotere (docetaxel) by Sanofi
Cyramza (ramucirumab) by Eli Lilly
Zykadia (ceritinib) by Novartis
Opdivo (nivolumab) by Bristol-Myers Squibb

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• The US
• Japan
• Germany
• France
• Italy
• Spain
• The UK
• China
• Brazil
• Russia
• India
• Rest of the World

• This report also includes a chapter on R&D which discusses some of the most promising and prominent late-stage candidates

• Our study includes a SWOT analysis of this industry and market

• Our study explores the issues and forces that influence the NSCLC drugs market:
• Genetic mutations allowing for targeted therapies, newer medicines offering improved treatment outcomes
• Treatment protocols by stage and for patient populations – maintenance, second-line and third-line therapies
• Regulators’ views and cost-effectiveness – challenges and opportunities in drug approvals, pricing, reimbursement and healthcare budgets
• Recent approval for the NSCLC indication – expanding treatment options
• Overcoming patent expiries and competition from generic drugs
• Identification of biomarkers for targeted therapies, advancing treatment protocols.

Visiongain’s study is intended for anyone requiring commercial analyses for the Non-Small Cell Lung Cancer (NSCLC) Drugs market. You find data, trends and predictions.

Buy our report today Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027: Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, Other.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

READ

Categories